When a Gibson, Dunn & Crutcher team defended Sanofi-Aventis SA against novel accusations that it defrauded the government by improperly getting a drug patent, it had to master a lot of sophisticated scientific concepts. But in the end, the case boiled down to something more digestible: the credibility of one of their opponent’s main witnesses on the stand.
“In every lawsuit—no matter how complicated it is—the issue can oftentimes be stated very simply,” said Gibson Dunn ‘s William Dawson, who led Sanofi’s legal team.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
